United Kingdom Archives

News and Trends 25 Feb 2015

Ipsen buys an option to Acquire Canbex

Canbex, a spin-off of University College London (UCL) that raised a Series A financing of €2.8M in 2013 from MS Ventures, may become part of Ipsen. The French giant payed €6M upfront for the option to purchase 100% of Canbex shares upon completion of the Phase IIa study of Canbex’s lead candidate for the treatment […]

February 25, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 24 Feb 2015

Cobra Biologics and Manchester University Awarded €296.4K

The University of Manchester and Cobra Biologics, biologics and pharmaceuticals manufacturer, have been awarded €296.4K by Innovate UK and the Biotechnology and Biological Sciences Research Council (BBSRC). The project is one of the only 23 which will share almost €27.3M given away by the competition that intends to bring innovative biotechnology projects to market. The joint […]

February 24, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 16 Feb 2015

Great news for Great Britain’s synthetic biology

British government will inject the impressive amount of £40M to reinforce UK’s leading position in synthetic biology. UK Business Secretary Vince Cable has announced a £40M investment in UK synthetic biology at the Manchester Institute for Biotechnology. The majority of this investment, £32M, will be used to establish three new Synthetic Biology Research Centres at […]

February 16, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 14 Feb 2015

GlycoVaxyn: A new Gain for GSK’s Vaccines Business

GSK, who was already a minority shareholder in GlycoVaxyn, acquires the company and its biological conjugation platform which may help it to develop a new generation of prophylactic vaccines against bacterial infections. GSK has today paid €167M to purchase the remaining stake in the company. GlycoVaxyn’s innovative biological conjugation platform originates enables the development of […]

February 14, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 6 Feb 2015

2014, the Biggest Year Ever for European Biotech IPOs

There is no need to say it: biotechnology is the latest trend. A worldwide bio-boom has shaken stock markets throughout 2014. For European start-ups, last year represented a remarkable step forward as 15 companies went public and raised €719.8M in total, as Biocom’s last report states. Let me present you a review summering the major […]

February 6, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 2 Feb 2015

Will 4D Pharma be UK’s next Microbiome leader?

4D Pharma, a biopharmaceutical company focusing on significant new therapeutic areas, plan to raise €46M to continue the development of its drugs candidates and to exploit its microbiome platform MicroRx. Will 4DPharma be the next UK’s microbiome leader? This English company, founded in early 2014, has focused its current interests solely in the microbiome field and the discovery […]

February 2, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 31 Jan 2015

An Anglo-French Partnership To Cure Hepatitis B

European biotechnology company Valneva and UK company Immune Targeting Systems (ITS) announced that they have signed an exclusive worldwide commercial license agreement. This deal grants ITS the rights to research, develop and commercialize Hepatitis B vaccine candidates in combination with Valneva’s IC31 Adjuvant. Valneva’s IC31 Adjuvant is a unique synthetic adjuvant combining the immuno-stimulating properties […]

January 31, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 24 Jan 2015

Important Bilateral Academic Agreement for the Future of iPS Cell Therapy

The UK Cell Therapy programme Catapult, which is focused on the development of the UK cell therapy industry to increase the nation’s health and wealth, has signed a patent licence agreement with iPS Academia Japan. It represents a pivotal step in the development of the UK’s GMP induced pluripotent stem (iPS) cell bank. Under the […]

January 24, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 22 Jan 2015

Novabiotics Tackles Antibiotic Resistance by Raising €6,5M Euros

NovaBiotics Ltd has raised €6,5M for priority clinical stage first-in-class antimicrobial therapeutics assets. The private placement with Woodford Investment Management LLP was arranged by Shore Capital as financial adviser and broker to the company. NovaBiotics is a clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. NovaBiotics has spent more than 10 […]

January 22, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 10 Dec 2014

Promising Agreement Signed for Regenerative Medicine

Heraeus Medical signed an agreement with Locate Therapeutics to license the intellectual property surrounding the use of TAOS in orthopaedic applications and the inception of the first development program in this field. The agreement gives Heraeus Medical GmbH the rights to the future co-developed orthopaedic products as well as the processes involved in manufacturing the final product. […]

December 10, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 28 Nov 2014

One Billion Strategic Oncology Alliance for the Second Largest Antibody Technology Platform

Oxford BioTherapeutics and Menarini Group have initiated the first-in-human clinical study of OBT357, a novel enhanced antibody for the treatment of acute myeloid leukemia (AML). This is the first of five development programs between the two companies to enter the clinic in a $1 billion strategic oncology alliance. Oxford BioTherapeutics and the Menarini Group established their […]

November 28, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 22 Nov 2014

After AstraZeneca Turned Down Pfizer’s Bid, Merck Took the Opportunity

Pharmaceutical giants Merck and Pfizer have agreed a deal to develop and market immunotherapy agents to fight cancer. Now, the last Pfizer’s proposal to AstraZeneca is pending. Merck will get an upfront payment of €682 million from the U.S. drugmaker for sharing rights to develop its experimental immunotherapy drug with Pfizer. It is also eligible […]

November 22, 2014 - 2 minutesmins - By Julie Lellouche

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

United Kingdom

Ipsen buys an option to Acquire Canbex

Cobra Biologics and Manchester University Awarded €296.4K

Great news for Great Britain’s synthetic biology

GlycoVaxyn: A new Gain for GSK’s Vaccines Business

2014, the Biggest Year Ever for European Biotech IPOs

Will 4D Pharma be UK’s next Microbiome leader?

An Anglo-French Partnership To Cure Hepatitis B

Important Bilateral Academic Agreement for the Future of iPS Cell Therapy

Novabiotics Tackles Antibiotic Resistance by Raising €6,5M Euros

Promising Agreement Signed for Regenerative Medicine

One Billion Strategic Oncology Alliance for the Second Largest Antibody Technology Platform

After AstraZeneca Turned Down Pfizer’s Bid, Merck Took the Opportunity

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!